Metropolitan Life Insurance Company (MetLife)’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,817	Closed	-$5.8K	–	2228
2024 Q1	$5.8K	Sell	1,817 -1,946	-52%	-$6.49K	﹤0.01%	2238
2023 Q4	$12.6K	Hold	3,763	–	–	﹤0.01%	2101
2023 Q3	$8.96K	Hold	3,763	–	–	﹤0.01%	2257
2023 Q2	$6.62K	Buy	+3,763	New	+$9.61K	﹤0.01%	2439
2021 Q2	–	Sell	-9,154	Closed	-$87.4K	–	2906
2021 Q1	$87.4K	Buy	+9,154	New	+$89.8K	﹤0.01%	2459

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PSTX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2024, closing a stake of 1,817 shares — an estimated $5.8K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PSTX in Q1 2021 and held it in 5 quarters. The position peaked at $87.4K in Q1 2021. 93 funds tracked by Wall St. Rank hold PSTX as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,817 Poseida Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $5.8K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Metropolitan Life Insurance Company (MetLife)'s Poseida Therapeutics, Inc. Common Stock position peaked at $87.4K in Q1 2021.
93 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.